60 Participants Needed

Vision Training for Age-Related Macular Degeneration

(FLAP Trial)

KV
RC
RA
KM
Overseen ByKristina M Visscher, Ph.D.
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores new methods to assist individuals with age-related macular degeneration, a condition that causes vision loss. It examines whether eye training can improve vision by testing two methods: one focuses on visual sensitivity (Training visual sensitivity), and the other combines various visual tasks (Combination training). Individuals diagnosed with macular degeneration, who have severely impaired vision in both eyes and have experienced these issues for at least two years, might be suitable candidates. The research aims to discover treatments that could benefit millions facing vision loss. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that may lead to new treatments for vision loss.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What prior data suggests that this vision training is safe for individuals with age-related macular degeneration?

Research has shown that training the eyes to see better can aid individuals with age-related macular degeneration (AMD). Some studies have found that vision can improve through exercises that enhance the ability to notice details more clearly. This training is generally safe, as it relies on exercises rather than drugs or surgery.

For training that combines various exercises, specific safety information remains less clear. However, since it involves exercises and not medication, it is likely low-risk. These methods are non-invasive, meaning they don't involve surgery or drugs, which typically results in fewer side effects.12345

Why are researchers excited about this trial?

Researchers are excited about the Vision Training for Age-Related Macular Degeneration because it offers a unique approach compared to traditional treatments like anti-VEGF injections. Unlike these standard therapies that mainly focus on slowing disease progression by targeting blood vessel growth, this trial explores perceptual learning techniques to enhance visual processing. The "Training visual sensitivity" arm specifically aims to improve how the brain processes visual information, potentially enhancing visual acuity through exercises with Gabor patches. Meanwhile, the "Combination training" arm combines visual sensitivity training with spatial integration tasks, potentially offering synergistic benefits that surpass the effects of either method alone. This innovative focus on retraining the brain's visual processing is what makes these treatments stand out.

What evidence suggests that this trial's treatments could be effective for age-related macular degeneration?

Research has shown that training to enhance visual acuity can benefit individuals with age-related macular degeneration (AMD). Studies have found that this training can clarify and sharpen vision, assisting with everyday tasks and making daily activities easier for those with low vision. In this trial, participants will join different treatment arms. One arm will focus on training visual sensitivity, which has shown promise in improving acuity. Another arm will explore combination training, where researchers are investigating whether combining different training methods proves more effective than using just one. Although the effectiveness of this combination is still under study, early results suggest it might improve overall vision.678910

Are You a Good Fit for This Trial?

This trial is for adults aged 18-89 with severe vision impairment (20/100 or worse) due to Macular Degeneration, confirmed by an ophthalmologist. Participants must have had this condition for at least two years and live within 50 miles of the study site. Those with certain body measurements, metal implants, claustrophobia, hearing impairments, significant head injuries, mental health conditions like hallucinations/delusions, or specific tattoos near the head cannot join.

Inclusion Criteria

My medical records show my condition has been severe for at least 2 years.
Reside within 50 miles of study site
You have very poor vision in both eyes (20/100 or worse).
See 2 more

Exclusion Criteria

You weigh more than 300 pounds.
You have had a severe head injury in the past.
You have too many, or very colorful tattoos, especially near your head.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Training

Participants undergo perceptual learning training focusing on visual sensitivity, spatial integration, and attention and eye-movements.

7 weeks
Weekly sessions

Follow-up

Participants are monitored for changes in visual processing and brain plasticity after training completion.

3 weeks
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Combination training
  • Training visual sensitivity
Trial Overview The study explores how different training methods can improve visual sensitivity in people suffering from low vision caused by Macular Degeneration. It aims to understand how the brain adapts and learns despite central vision loss which could lead to new treatments that help preserve sight.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Training visual sensitivityExperimental Treatment1 Intervention
Group II: Combination trainingExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

University of California, Riverside

Collaborator

Trials
33
Recruited
14,400+

Published Research Related to This Trial

A survey of 136 optometrists revealed that 68% are private practitioners, and most provide low vision rehabilitation training for 1 hour or less, indicating a potential gap in comprehensive training for patients with moderate visual impairment.
The study highlights the need for standardized terminology and management criteria in low vision rehabilitation, suggesting that more clinical research and education are necessary to improve the effectiveness and accessibility of care for patients with vision impairment.
Survey of optometric low vision rehabilitation training methods for the moderately visually impaired.Kammer, R., Sell, C., Jamara, RJ., et al.[2015]
A training program focused on oculomotor control significantly increased reading speed by an average of 24.7 words per minute in 16 patients with age-related macular degeneration (AMD) over an 8-week period.
The training emphasized eye movement exercises rather than direct reading practice, suggesting that improving eye movement control can enhance reading abilities in AMD patients, regardless of their visual acuity or age.
Eye-movement training for reading in patients with age-related macular degeneration.Seiple, W., Szlyk, JP., McMahon, T., et al.[2006]
In a study of patients with advanced age-related macular degeneration (AMD), visual rehabilitation using an acoustic biofeedback training system significantly improved various visual functions, including visual acuity and contrast sensitivity.
The training involved ten sessions of 10 minutes each, conducted twice a week, and resulted in enhanced quality of life for patients by helping them shift fixation from damaged areas of the retina to healthier regions.
Efficacy of biofeedback rehabilitation based on visual evoked potentials analysis in patients with advanced age-related macular degeneration.Verdina, T., Piaggi, S., Ferraro, V., et al.[2021]

Citations

Improving Outcomes for Patients with Age-Related Macular ...Currently there is no effective treatment for the majority of patients suffering from dry AMD. Cataract and AMD often coexist in patients. In ...
Eccentric Viewing Training for Age-Related Macular DiseaseOn average, visual acuity deteriorated by 0.20 logMAR (SD: 0.47) over the study, from a mean value of 0.67 logMAR (SD: 0.24) to 0.87 logMAR (SD: 0.41). There ...
Re: Rubin et al: Eccentric Viewing Training for Age-related ...Rubin et al.: Eccentric Viewing Training for Age-Related Macular Disease: Results of a Randomized Controlled Trial (the EFFECT Study)
Predicting risk of late age-related macular degeneration ...Here, we demonstrate how deep learning and survival analysis can predict the probability of progression to late AMD using 3298 participants ( ...
Effectiveness of eccentric viewing training for daily visual ...Meta-analysis was conducted to examine effectiveness of eccentric viewing training on daily visual activities for individuals with age-related ...
Combination Therapy for Age-Related Macular ...This randomized, controlled trial addresses the potential supplemental therapeutic effect of intravitreal injection of Triamcinolone Acetonide ...
Rethinking Clinical Trials in Age-Related Macular DegenerationThis review highlights the transformative potential of AI in optimizing clinical trial outcomes for patients with nAMD or GA secondary to AMD.
Combined automated screening for age-related macular ...The AMD and DR screening tools achieved excellent performance operating together to identify two retinal diseases prospectively in mixed datasets, demonstrating ...
Age-related macular degeneration: Epidemiology, genetics ...Age-related macular degeneration (AMD) is a complex eye disorder and is the leading cause of incurable blindness worldwide in the elderly.
A Study to Evaluate the Safety and Efficacy of RQC for AMDTo evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security